The newly established human hepatocyte cell line

Application for the bioartificial liver

Norifumi Harimoto, Akinobu Taketomi, Dai Kitagawa, Yohsuke Kuroda, shinji itoh, Tomonobu Gion, Shinji Tanaka, Ken Shirabe, Mitsuo Shimada, Yoshihiko Maehara

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background/Aims: Human hepatocyte cell lines are reported to lose many of their biochemical functions in a hybrid artificial liver support system (HALSS). Differentiation therapy is useful to up-regulate liver function. Methods: The human hepatoblastoma cell line HepG2 was transfected with HSV/tk gene. Albumin synthesis and ammonia removal activity were evaluated when HepG2/tk was cultured with histone deacetylase inhibitor (FR228) and peroxisome proliferator activated receptor-gamma ligand (pioglitazone). To investigate the function of HepG2/tk in vivo, cell transplantation for 90% hepatectonized rats was conducted. Results: We established stable cell lines which expressed HSV/tk and were sensitive to gancyclovir in vitro and in vivo. Both albumin synthesis rate and ammonia removal rate improved for HepG2/tk incubated with FR228 and pioglitazone for 3 days, which induced nuclear transport of p21. Rats with intrasplenic injection of HepG2/tk precultured for 3 days with FR228 and pioglitazone survived significantly longer than the control rats. The ammonia and total bilirubin concentrations were significantly lower in the test group than in the control group. The injection of gancyclovir inhibited the prolonged survival of the rats with precultured HepG2/tk. Conclusions: HepG2/tk is safe as well as enhancing high levels of liver function. It will be a potential cell source for HALLS in the future.

Original languageEnglish
Pages (from-to)557-564
Number of pages8
JournalJournal of Hepatology
Volume42
Issue number4
DOIs
Publication statusPublished - Jan 1 2005

Fingerprint

pioglitazone
Artificial Liver
Hepatocytes
Ammonia
Cell Line
Ganciclovir
Albumins
Hepatoblastoma
Injections
Histone Deacetylase Inhibitors
Cell Nucleus Active Transport
PPAR gamma
Liver
Cell Transplantation
Bilirubin
Up-Regulation
Ligands
Control Groups
Genes

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Harimoto, N., Taketomi, A., Kitagawa, D., Kuroda, Y., itoh, S., Gion, T., ... Maehara, Y. (2005). The newly established human hepatocyte cell line: Application for the bioartificial liver. Journal of Hepatology, 42(4), 557-564. https://doi.org/10.1016/j.jhep.2004.11.038

The newly established human hepatocyte cell line : Application for the bioartificial liver. / Harimoto, Norifumi; Taketomi, Akinobu; Kitagawa, Dai; Kuroda, Yohsuke; itoh, shinji; Gion, Tomonobu; Tanaka, Shinji; Shirabe, Ken; Shimada, Mitsuo; Maehara, Yoshihiko.

In: Journal of Hepatology, Vol. 42, No. 4, 01.01.2005, p. 557-564.

Research output: Contribution to journalArticle

Harimoto, N, Taketomi, A, Kitagawa, D, Kuroda, Y, itoh, S, Gion, T, Tanaka, S, Shirabe, K, Shimada, M & Maehara, Y 2005, 'The newly established human hepatocyte cell line: Application for the bioartificial liver', Journal of Hepatology, vol. 42, no. 4, pp. 557-564. https://doi.org/10.1016/j.jhep.2004.11.038
Harimoto, Norifumi ; Taketomi, Akinobu ; Kitagawa, Dai ; Kuroda, Yohsuke ; itoh, shinji ; Gion, Tomonobu ; Tanaka, Shinji ; Shirabe, Ken ; Shimada, Mitsuo ; Maehara, Yoshihiko. / The newly established human hepatocyte cell line : Application for the bioartificial liver. In: Journal of Hepatology. 2005 ; Vol. 42, No. 4. pp. 557-564.
@article{a74a3a79e99c4662a68e5ee8d1970062,
title = "The newly established human hepatocyte cell line: Application for the bioartificial liver",
abstract = "Background/Aims: Human hepatocyte cell lines are reported to lose many of their biochemical functions in a hybrid artificial liver support system (HALSS). Differentiation therapy is useful to up-regulate liver function. Methods: The human hepatoblastoma cell line HepG2 was transfected with HSV/tk gene. Albumin synthesis and ammonia removal activity were evaluated when HepG2/tk was cultured with histone deacetylase inhibitor (FR228) and peroxisome proliferator activated receptor-gamma ligand (pioglitazone). To investigate the function of HepG2/tk in vivo, cell transplantation for 90{\%} hepatectonized rats was conducted. Results: We established stable cell lines which expressed HSV/tk and were sensitive to gancyclovir in vitro and in vivo. Both albumin synthesis rate and ammonia removal rate improved for HepG2/tk incubated with FR228 and pioglitazone for 3 days, which induced nuclear transport of p21. Rats with intrasplenic injection of HepG2/tk precultured for 3 days with FR228 and pioglitazone survived significantly longer than the control rats. The ammonia and total bilirubin concentrations were significantly lower in the test group than in the control group. The injection of gancyclovir inhibited the prolonged survival of the rats with precultured HepG2/tk. Conclusions: HepG2/tk is safe as well as enhancing high levels of liver function. It will be a potential cell source for HALLS in the future.",
author = "Norifumi Harimoto and Akinobu Taketomi and Dai Kitagawa and Yohsuke Kuroda and shinji itoh and Tomonobu Gion and Shinji Tanaka and Ken Shirabe and Mitsuo Shimada and Yoshihiko Maehara",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.jhep.2004.11.038",
language = "English",
volume = "42",
pages = "557--564",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - The newly established human hepatocyte cell line

T2 - Application for the bioartificial liver

AU - Harimoto, Norifumi

AU - Taketomi, Akinobu

AU - Kitagawa, Dai

AU - Kuroda, Yohsuke

AU - itoh, shinji

AU - Gion, Tomonobu

AU - Tanaka, Shinji

AU - Shirabe, Ken

AU - Shimada, Mitsuo

AU - Maehara, Yoshihiko

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background/Aims: Human hepatocyte cell lines are reported to lose many of their biochemical functions in a hybrid artificial liver support system (HALSS). Differentiation therapy is useful to up-regulate liver function. Methods: The human hepatoblastoma cell line HepG2 was transfected with HSV/tk gene. Albumin synthesis and ammonia removal activity were evaluated when HepG2/tk was cultured with histone deacetylase inhibitor (FR228) and peroxisome proliferator activated receptor-gamma ligand (pioglitazone). To investigate the function of HepG2/tk in vivo, cell transplantation for 90% hepatectonized rats was conducted. Results: We established stable cell lines which expressed HSV/tk and were sensitive to gancyclovir in vitro and in vivo. Both albumin synthesis rate and ammonia removal rate improved for HepG2/tk incubated with FR228 and pioglitazone for 3 days, which induced nuclear transport of p21. Rats with intrasplenic injection of HepG2/tk precultured for 3 days with FR228 and pioglitazone survived significantly longer than the control rats. The ammonia and total bilirubin concentrations were significantly lower in the test group than in the control group. The injection of gancyclovir inhibited the prolonged survival of the rats with precultured HepG2/tk. Conclusions: HepG2/tk is safe as well as enhancing high levels of liver function. It will be a potential cell source for HALLS in the future.

AB - Background/Aims: Human hepatocyte cell lines are reported to lose many of their biochemical functions in a hybrid artificial liver support system (HALSS). Differentiation therapy is useful to up-regulate liver function. Methods: The human hepatoblastoma cell line HepG2 was transfected with HSV/tk gene. Albumin synthesis and ammonia removal activity were evaluated when HepG2/tk was cultured with histone deacetylase inhibitor (FR228) and peroxisome proliferator activated receptor-gamma ligand (pioglitazone). To investigate the function of HepG2/tk in vivo, cell transplantation for 90% hepatectonized rats was conducted. Results: We established stable cell lines which expressed HSV/tk and were sensitive to gancyclovir in vitro and in vivo. Both albumin synthesis rate and ammonia removal rate improved for HepG2/tk incubated with FR228 and pioglitazone for 3 days, which induced nuclear transport of p21. Rats with intrasplenic injection of HepG2/tk precultured for 3 days with FR228 and pioglitazone survived significantly longer than the control rats. The ammonia and total bilirubin concentrations were significantly lower in the test group than in the control group. The injection of gancyclovir inhibited the prolonged survival of the rats with precultured HepG2/tk. Conclusions: HepG2/tk is safe as well as enhancing high levels of liver function. It will be a potential cell source for HALLS in the future.

UR - http://www.scopus.com/inward/record.url?scp=20044389075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044389075&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2004.11.038

DO - 10.1016/j.jhep.2004.11.038

M3 - Article

VL - 42

SP - 557

EP - 564

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 4

ER -